and mortality in the time between baseline and follow-up. The European Union(7)-PIM list was used to evaluate PIM prescription. Multivariate regression analysis was used to investigate factors and adverse outcomes associated with PIM prescription. Results: overall, 60% of the participants had at least one PIM prescription and 26.4% at least two. The PIM therapeutic subgroups most frequently prescribed were psycholeptics (26% of all PIM prescriptions) and 'drugs for acid-related disorders' (21%). PwD who were 80 years and older, lived in institutional long-term care settings, had higher comorbidity and were more functionally impaired were at higher risk of being prescribed two PIM or more. The prescription of two or more PIM was associated with higher chance of suffering from at least one fall-related injury and at least one episode of hospitalisation in the time between baseline and follow-up. Conclusions: PIM use among PwD is frequent and is associated with institutional long-term care, age, advanced morbidity and functional impairment. It also appears to be associated with adverse outcomes. Special attention should be paid to psycholeptics and drugs for acid-related disorders.
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Background
Recent literature suggests that people with dementia (PwD) have more complex needs because of higher comorbidity and polypharmacy burden than people of comparable age but without dementia [1] .
A recently published literature review reported a prevalence of prescription of potentially inappropriate medications (PIM) ranging from 10 to 56% among PwD [2] . PIM are those drugs that should not usually be prescribed for older people because the risk of adverse effects outweighs the clinical benefit; there is often a safer or more effective alternative therapy for the same condition [3, 4] . The body of literature studying factors associated with and potential adverse consequences of PIM use specifically in PwD is limited, as is the number of studies focusing on nursing homes.
The 'RightTimePlaceCare (RTPC)' study is a European study that started in 2010 [5] and included a cohort of PwD from eight European countries. In order to analyse the prescription of PIM in this population, the European Union (EU)(7)-PIM list was developed, covering several European countries and using an expert consensus method [6] .
The aims of the present study are to evaluate prospectively the frequency of PIM prescription among communitydwelling and nursing-home populations of PwD from eight European countries, and to explore which factors may be associated with the prescription of PIM.
Methods
The RTPC study was a prospective survey conducted in eight European countries: England, Estonia, Finland, France, Germany, the Netherlands, Spain and Sweden. The baseline assessments were performed between November 2010 and April 2012, the follow-ups 3 months after. Detailed information about the study design has been published elsewhere [5] . Two groups were included: (i) PwD who were newly admitted to an institutional long-term care (ILTC) facility; and (ii) PwD who received home care but were at risk of admission to an ILTC facility within 6 months, as judged by a professional caregiver responsible for their care. Inclusion criteria were: (i) having an official diagnosis of dementia; (ii) scoring 24 points or lower on the Standardised Mini Mental State Examination (S-MMSE); and (iii) having an informal caregiver who visited them at least twice a month. PwD who were younger than 65 years of age and those with a primary psychiatric diagnosis of Korsakoff 's syndrome were excluded. Ethical approval was obtained by each country from the appropriate authority for research on human beings and informed consent was obtained from all participants. Trained interviewers interviewed the PwD, their informal caregivers and formal caregivers via face-to-face interviews.
Sample characteristics
Sociodemographic characteristics of the PwD were collected. Cognitive status was assessed with the S-MMSE (range: 0-30). The lower the score is, the greater is the cognitive impairment [7, 8] . Functional status was assessed with the Katz index of independence in activities of daily living (ADL) (range: 0-6). The lower the score is, the greater is the dependency in ADL [9] . Comorbidity was assessed with the Charlson comorbidity index (range: 0-32). The higher the score is, the greater is the presence of advanced comorbidity [10] . At follow-up, the caregivers were asked whether the PwD had suffered any episode of admission to hospital (including admission to hospital, to an emergency department for less than 24 h or to any other healthcare facility) since the last visit; they were also asked about the occurrence of any fall-related injury. Mortality at follow-up was assessed using a protocol that was established for those participants with early follow-up termination [5] .
Use of medication
Medication data were obtained from the previously advised formal or informal caregivers as part of the Resource Utilisation in Dementia tool at both baseline and follow-up [11, 12] . Client record files and medications were checked if necessary. An adaptation of this tool was agreed on for this project with the permission of the tool's first author in order to widen the information obtained on medication use and improve feasibility. Data collection forms included information about the drug name currently prescribed to the PwD, the anatomical therapeutic chemical ATC code, dose and frequency of use, and administration route. The English 2011 version of the ATC code classification system was applied [13] . Drugs were classified according to whether they were used regularly or irregularly (drugs used on demand and other drugs used for limited periods of time, such as antibiotics). Each baseline medication was classified into 'PIM' or 'not PIM' according to the EU(7)-PIM list [6] . This list comprises 282 chemical substances or drug classes from 34 therapeutic groups considered to be PIM; it focuses on drugs with systemic effects, and some PIM are restricted to a certain dose or usage time. Follow-up medication data were used to classify those PIM restricted to a certain usage time.
Frequency of PIM prescription at baseline and analysis of factors associated
For each individual country and for all the countries together, we calculated the frequency of PwD being prescribed ≥1 PIM and ≥2 PIM at baseline; besides, we identified the 10 most frequently prescribed therapeutic subgroups and PIM. PIM that were prescribed both regularly and irregularly were considered.
For the analysis of factors associated with PIM prescription, a statistical model was planned where the dependent variable was 'prescription of ≥2 PIM on a regular or irregular basis'. We chose this variable instead of the 'prescription of ≥1 PIM' most often used in the literature because we considered that the prescription of one PIM only could be more easily justifiable for individual cases. We included both regular and irregular PIM prescriptions because we considered that both types of prescriptions are to be avoided. After literaturebased team discussion we predefined the following independent variables: age (>80 versus ≤80), gender (male versus female), functional status (Katz index; categories 0-2, 3-5 and 6), cognitive status (MMSE; categories 0-9, 10-19 and 20-24), comorbidity (Charlson index ≥3 versus <3), setting (nursing home versus home care).
A second statistical model was planned to analyse adverse outcomes associated with PIM prescription. After literature-based team discussion and taking the design and variables of the RTPC study into consideration, the following variables were chosen: 'mortality after 3 months', 'at least one episode of fall-related injury after 3 months', and 'at least one episode of hospitalisation after 3 months'. The same independent variables as for the first model were considered for this model in addition to the variable 'use of PIM (categories: 0, 1 and ≥2 PIM prescribed in a regular way) ' . A further analysis also incorporated polypharmacy (categories: ≤4, 5-9, ≥10 systemic regular drugs prescribed)
as an independent variable. The research team decided to consider only regular PIM prescriptions in order to focus on those participants who were probably more exposed to PIM.
Statistical analyses
The results of the descriptive analyses are presented with mean values and the corresponding standard deviation for continuous variables with a normal distribution, median values and the corresponding interquartile range for continuous variables without a normal distribution, and percentages for discrete variables. Multivariate logistic regression analysis was performed for follow-up analysis to control for several confounding variables, including age, sex, functional status and comorbidity. The results are presented as odds ratios (OR) with 95% confidence intervals (CI). P values less than 0.05 were considered statistically significant. The SAS version 9.4 (copyright 2002-12 by SAS Institute Inc., Cary, NC, USA) was used. A complete case analysis was performed, including only cases without missing values.
Results
The study sample consisted of 2,004 PwD with a mean age of 83 (6.6); 67.5% were female, 39.3% lived in nursing homes, they had a median MMSE score of 14, median Katz index score of 3, and a median Charlson index score of 2. From this sample, 6.6% died, 16.7% were hospitalised at least once and 11.3% suffered at least one fall-related injury after 3 months. Supplementary data, Table Appendix 1 available at Age and Ageing online displays detailed data on the characteristics of the participants.
All the PIM on the EU(7)-PIM list were applicable to the RTPC database apart from one. The database could not be used to detect the PIM 'codeine used longer than 2 weeks' because the information on short-term drug use was not detailed enough. Age older than 80 years, higher dependency in ADLs, higher comorbidity and living in an ILTC facility were associated with the prescription of ≥2 PIM. Lower S-MMSE scores (0-9) were associated with less frequent prescription of ≥2 PIM when compared with higher S-MMSE scores (20) (21) (22) (23) (24) (Table 1 ). 
% (n) of all PIM prescriptions
Eleven most frequently prescribed PIM therapeutic subgroups b n = 1,229 participants with complete data (n = 419 participants with ≥2 PIM prescriptions), participants with 1 PIM prescription not considered.
In the second statistical model, the prescription of ≥2 PIM compared with no PIM prescription was associated with the higher chance of suffering at least one fall-related injury (OR: 1.54 (95% CI: 1.04-2.30); P = 0.033) and with the higher chance of undergoing at least one episode of hospitalisation (OR: 1.6 (95% CI: 1.13-2.27); P = 0.008) between baseline and follow-up (see Supplementary data, 
Discussion
Our analysis across eight European countries revealed a remarkably high frequency of PIM prescriptions among PwD, where sixty percent of all RTPC participants were prescribed at least one PIM and 26% were prescribed at least two PIM. Estonia and Sweden were the countries with lower frequencies of PIM prescription. While in Estonia this may be explained by a lower number of drugs prescribed per participant, the mean number of drugs prescribed per participant in Sweden was similar to that in the overall European sample. In the review conducted by Johnell in 2015, most studies reported a prevalence of PIM use among PwD or people with cognitive impairment ranging from 20 to 56.4% [2] . The high frequency of PIM prescriptions in the present study could have been influenced by the fact that our sample included PwD who were especially frail (i.e. those who are at risk of admission to ILTC facilities or those who have been recently admitted).
Our study identified and described some prescribing similarities and differences between European countries, which may be a reflection on the variations in guidelines and prescribing habits across countries. The PIM therapeutic subgroup of psycholeptics was the most frequently prescribed subgroup in the whole European sample, with 'Risperidone used longer than 6 weeks' being the second most frequently prescribed PIM; this PIM was in the 'top 10 PIM list' of all the countries with the exception of France and England. This is in accordance with the intercountry variations observed in the RTPC cohort when analysing the prescriptions of antipsychotics [14] . Other studies have also identified psycholeptics as being frequently prescribed PIM [15, 16] . Given the risk associated with long-term use of neuroleptics [17] and hypnotics [18] among PwD, strategies other than medication are needed with the aim of improving the management of neuropsychiatric symptoms of dementia; some interventions have recently been evaluated and some have shown positive results [19, 20] .
The PIM therapeutic subgroup 'drugs for acid-related disorders' was the second most frequently prescribed subgroup, and 'proton-pump inhibitors used longer than 8 weeks' was the most frequently prescribed PIM in the whole European sample and also in each of the individual countries with the exception of Estonia. This was also one of the most frequently prescribed PIM among community older people according to the STOPP/START criteria [15] . The high frequency of use of proton-pump inhibitors without a justified indication [21] and its possible association with adverse consequences [22] suggests that interventions focussed at avoiding their inappropriate prescription are necessary, some of which are being assessed [23] .
PIM prescription (≥2 PIM) was associated with being ≥80 years old, having higher comorbidity, being moderately or severely functionally impaired, having mild cognitive impairment compared with severe cognitive impairment, and living in ILTC facilities. Previous studies suggested similar associations between PIM prescription and age [24] , comorbidity [24, 25] , functional status [25] , living facility [26] and cognitive status [2] . The association between severe cognitive impairment and reduced PIM use could be due to a combination of reasons such as a lack of detection of certain clinical problems in this population, or more cautious prescribing habits of the clinicians [2] .
In the present study, the prescription of ≥2 PIM was associated with a higher risk of suffering a fall-related injury and a higher risk of undergoing at least one hospitalisation during a period of 3 months. The higher risk of hospitalisation associated with PIM use has been described in the literature [27, 28] . In addition, PIM use has been found to be associated with hospitalisation due to fall-induced osteoporotic fractures [29] . However, it should be acknowledged that the association was weakened by the polypharmacy variable. As our analysis was adjusted for comorbidity, this implies that the number of drugs prescribed (PIM or otherwise)-apart from being a marker for multi-morbidity-appears to increase the risk of adverse events [30] .
This study has limitations and strengths. The RTPC sample may not be representative for the national populations. However, the samples coming from the different European countries were more comparable due to the joint inclusion criteria. The short follow-up period of the study limits the interpretation of the long-term consequences of PIM use. The prospective design is one of the study's strengths.
The EU(7)-PIM list is an explicit screening tool that cannot assess individual aspects of prescription appropriateness. However, all criteria except one could be applied to the database with only a few clinical data being needed. Moreover, the tool was developed with the collaboration of experts from the same European countries as the RTPC project. Although the EU(7)-PIM list is not specific for dementia, the RTPC sample can be seen as an important group of vulnerable older people.
Conclusions
This is the first study that prospectively evaluates the prescription of PIM among PwD from different European countries. The EU(7)-PIM list identified a remarkably high frequency of PIM prescriptions. Similarities and differences between countries with regard to PIM prescription patterns were identified.
The PIM therapeutic subgroups of psycholeptics and 'drugs for acid-related disorders' were the most frequently prescribed. Interventions aimed at improving their prescription seem to be needed. Especially vulnerable for being prescribed PIM may be those PwD who are older (≥80 years), who live in an ILTC facility, have higher comorbidity and are functionally more impaired. These PwD may benefit especially from interventions aimed at improving prescription appropriateness. Further studies should investigate whether the prescription of PIM according to the EU(7)-PIM list is associated with adverse outcomes beyond polypharmacy and whether the application of the PIM list can help improving prescription appropriateness for older PwD.
Key points
• Overall, 60% of the people with dementia participating in the European 'RightTimePlaceCare' study had at least one potentially inappropriate medication (PIM) prescription.
• People with dementia who were older, more functionally impaired and those with higher comorbidities were at higher risk of PIM prescription.
• People with dementia admitted to long-term care facility settings were at higher risk of being prescribed two PIM or more.
• Psycholeptics and drugs for acid-related disorders were the most prescribed PIM therapeutic subgroups in the European sample.
• PIM prescription was associated with higher risk of fallrelated injuries and hospitalisation.
Supplementary Data
Supplementary data are available at Age and Ageing online.
